Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rofecoxib.

J L Hillson1, D E Furst

  • 1Virginia Mason Medical Centre and Virginia Mason Research Centre, 1100 Ninth Avenue, Seattle, WA 98101, USA.

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Rofecoxib, a selective COX-2 inhibitor, effectively treats pain and inflammation with less gastrointestinal toxicity than traditional NSAIDs. However, potential side effects like edema and hypertension warrant careful consideration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).

Clinical rheumatology·2019
Same author

Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Journal of scleroderma and related disorders·2018
Same author

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Atherosclerosis·2018
Same author

Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review.

Lupus·2018
Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Rheumatology

Background:

  • Rofecoxib is an orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for pain, fever, dysmenorrhea, and osteoarthritis.
  • It selectively inhibits cyclooxygenase-2 (COX-2), targeting prostanoid synthesis in inflammatory cells.

Purpose of the Study:

  • To evaluate the efficacy and safety profile of rofecoxib compared to other NSAIDs.
  • To assess its potential for reduced gastrointestinal (GI) toxicity due to COX-2 specificity.

Main Methods:

  • Clinical trials comparing rofecoxib with ibuprofen, diclofenac, and indomethacin.
  • Assessment of GI toxicity through endoscopy, GI blood loss measurements, and analysis of serious adverse GI events.

Main Results:

Related Experiment Videos

  • Rofecoxib demonstrated comparable efficacy to other NSAIDs in managing pain and inflammation.
  • Significantly less GI toxicity was observed with rofecoxib, evidenced by fewer lesions, reduced blood loss, and fewer serious GI events.
  • Common NSAID side effects such as peripheral edema and hypertension were dose-dependent.

Conclusions:

  • Rofecoxib offers an effective therapeutic option for pain and inflammation with a favorable GI safety profile.
  • Potential dose-dependent side effects and cost-benefit considerations require attention in clinical practice.